retatrutide clinical trial germany UK: Online Clinically Led Weight Loss Treatment Retatrutide: Effects and Current Status

We handle every case with the dedication and trial-readiness that gives our clients real negotiating power

Retatrutide is still being studied and is not yet approved for general use, which simply means we rely on current data to guide expectations instead of making promises

Most respondents were of European ancestry (78.3%), although the study also included substantial representation from Latino (12.9%) and African American (4.2%) ancestries

Primary completion was October 1, 2025

When a Patient Should Discuss Heart Risk Before GLP-1 Therapy Patients should discuss cardiovascular risk before starting GLP-1 therapy if they have a history of heart attack, stroke, coronary artery disease, stents, heart failure, high blood pressure, high cholesterol, diabetes, kidney disease, sleep apnea, fatty liver disease, or a strong family history of heart disease